eligibility_summary
Eligible: adults ≥18 with unresectable/metastatic solid tumors lacking curative options post-SoC, types include non-NP head/neck, NSCLC, melanoma, cervical/ovarian/anal/genital, others per TScan. Require HLA A01:01/A02:01/B07:02/C07:02 and tumor MAGE-A1/A4/C2, PRAME or HPV16 (TSCAN-003), ECOG 0–1, measurable lesion, adequate organs. Exclude major cardiac disease, severe CRS/ICANS, recent stroke, high-dose steroids, allergy, CNS mets, other therapy, neuro risk, infection, HLA LOH w/o option, oxygen need.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Phase 1 basket of T-Plex, customized autologous TCR-engineered T cells (TCR-T, biological/cell therapy) given after lymphodepletion. Monotherapy or combinations of HLA-restricted products: TSC-204-A0201 (MAGE-A1/HLA-A02:01), TSC-204-C0702 (MAGE-A1/HLA-C07:02), TSC-204-A0101 (MAGE-A1/HLA-A01:01), TSC-201-B0702 (MAGE-C2/HLA-B07:02), TSC-202-A0201 (MAGE-A4/HLA-A02:01), TSC-203-A0201 (PRAME/HLA-A02:01), TSC-200-A0201 (HPV16 E7/HLA-A02:01). Mechanism: patient T cells are gene-modified to express high-affinity, antigen-specific TCRs that recognize peptide–HLA complexes on tumor cells, activating TCR/CD3 signaling and cytotoxic killing. Targets/pathways: cancer-testis antigens (MAGE-A1, MAGE-A4, MAGE-C2), PRAME, and viral HPV16 E7, HLA-restricted antigen presentation. T-Plex co-dosing aims to address tumor heterogeneity and HLA loss.